Two studies in US veterans find updated COVID vaccines protect against severe illness
Two new studies involving more than 1 million U.S. veterans suggest that updated COVID-19 vaccines continue to provide meaningful protection against severe illness.
Two recent studies have revealed that updated COVID-19 vaccines continue to offer protection against severe illness among U.S. veterans. The first study, published in Vaccine, discovered that the 2025-26 vaccine reduced emergency department visits by about 32% and hospitalizations by around 44%. The second study, appearing in JAMA Network Open, discovered that the 2025-26 Moderna vaccine provided more robust protection against medically attended COVID in older adults than Pfizer's vaccine.
In the first study, researchers from the Veterans Affairs (VA) Saint Louis Health Care System examined data from 931,943 veterans who received both a seasonal flu vaccine and a COVID vaccine. Over 180 days, COVID vaccination was linked with a 31.7% reduction in COVID-related emergency department visits and a 43.6% decrease in hospitalizations.
This indicates about seven fewer ED visits and three fewer hospitalizations per 10,000 people. The researchers note that although the absolute risk reductions were minor, these findings quantify the benefit of vaccination in a lower-incidence season and can guide clinical decision-making and seasonal vaccine policy. In the second study, researchers led by a team from VA Providence Healthcare System in Rhode Island compared the effectiveness of the Moderna and Pfizer vaccines among U.S. veterans aged 65 or older.
They found that the Moderna vaccine was associated with a 35.9% higher relative vaccine effectiveness, resulting in 10 fewer medically attended COVID cases per 10,000 vaccinated individuals. Additionally, the Moderna vaccine was linked to a 47.0% greater relative vaccine effectiveness in preventing hospitalization, leading to two fewer hospitalizations per 10,000 vaccinated people.
These findings suggest that the Moderna vaccine may provide more significant protection for older adults at high risk of severe COVID-19 outcomes, potentially influencing seasonal vaccine selection.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.